Patients with metastatic NSCLC harbouring genomic alteration of particular tyrosine kinases, notably epidermal growth factor receptor (EGFR), and rearrangements of the anaplastic lymphoma kinase (ALK) gene and c-ROS oncogene 1 (ROS1) gene, are treated with tyrosine kinase inhibitors (TKIs). This evidence concerns the gene ALK and non-small cell lung carcinoma.